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Table 1. Outcomes for PCI vs CABG for ULMCA occlusion presenting with
STEMI
Outcomes
PCI
(N¼26)
CABG
(N¼38)
P-
value
In - hospital Mortality, % (n) 15.4 (4) 34.2 (13) 0.04
In - hospital mortality, presenting with
cardiogenic shock, % (n)
30.8 (4/
13)
60 (6/10) 0.08
In - hospital Stroke, % (n) 0 5.2 (2) -
In - hospital MI, % (n) 3.8 (1) 0 -
In - hospital MACCE, % (n) 15.4 (4) 34.2 (13) 0.04
30 - day mortality, % (n) 19.2 (5) 34.2 (13) 0.09
All-cause mortality, % (n) 38.5
(10)
39.5 (15) 0.46
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comprocedure-related complications were observed, hospital and 30 day clinical outcomes
appeared to be good. However, further evaluation is needed.
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Background: Percutaneous coronary intervention (PCI) of left main stem (LMS)
bifurcation is technically challenging and remains the focus of active research.
Currently, LMS bifurcation lesions in the presence of concomitant complex coronary
disease are preferentially treated with coronary artery bypass grafting (CABG).
However, LMS lesions with low Syntax scores have similar long term results with PCI
in comparison to CABG. There are deﬁciencies with current two stent bifurcation
techniques namely being ostial side branch (SB) stenosis. The role of dedicated
bifurcation stents is expanding in this arena. We describe the world’s ﬁrst series of
treating LMS bifurcation lesions using a 7-French compatible self-expanding, nitinol-
based, biolimus-coated, 4.0 x 9 mm AXXESS stent.
Methods: Patients with bifurcation lesions were prospectively enrolled in this study.
The AXXESS stent was deployed at the carina followed by drug eluting stent (DES)
deployment in the distal main vessel (MV) or SB if indicated. The procedures were
carried out by experienced operators with a special interest in bifurcation lesion
treatment.
Results: Ten patients were treated with the 4.0 x 9 mm AXXESS dedicated bifur-
cation stent in two high-volume centres in the UK. All patients had true bifurcation
lesions and 90% patients required an additional stent in either the distal MV, SB or
both. The device was successfully deployed in all cases which translated into a lesion
success rate of 100%. Following a six-month follow-up, no major adverse cardiac
events were observed.
Conclusions: Our data suggest that the 4.0 x 9 mm AXXESS dedicated bifurcation
stent can be safely used and successfully delivered to treat appropriate LMS bifur-
cation lesions with excellent peri-procedural success rates and six-month outcome
data. We anticipate presenting six-month follow-up data with optical frequency
domain imaging.
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Background: Current guidelines recommend percutaneous coronary intervention
(PCI) as the initial mode of revascularization for patients presenting with ST elevation
myocardial infarction (STEMI), however there is an ongoing debate on the mode of
revascularization for unprotected left main coronary artery (ULMCA) occlusion
presenting as STEMI with limited data available in this ﬁeld. Here we compare the
outcomes in patients undergoing PCI vs coronary artery bypass graft surgery (CABG)
for ULMCA occlusion STEMI.
Methods: We studied consecutive adults presenting with STEMI who had a critical
ULMCA occlusion (>50%) at The Cleveland Clinic between 9/2005 – 9/2013. They
were categorized on the basis of revascularization strategy – CABG, PCI or medical
treatment. Our primary endpoint was in-hospital mortality, 30-day mortality and all-
cause mortality.
Results: A total of 72 patients (mean age 67.25  14.14 years, 54.2% men) had
ULMCA occlusion with STEMI (LM alone 29.2%). Out of which, 26 patients (mean
age 66.2  17.1 years, 50% men, 46.2% LM alone, syntax score 25.96  7.63, 50% in
cardiogenic shock, EF 38.77  14.59%) underwent PCI, 38 patients (mean age 65.8 
12.1 years, 60.5% men, 23.7% LM alone, syntax score 26.92  8.76, 26.3% in
cardiogenic shock, EF 39  15.39 %) underwent CABG, while 8 patients had medical
therapy alone. In-hospital mortality rates were signiﬁcantly lower in patients who
underwent PCI as compared to CABG, 30 day mortality tended to be lower with PCI,
at a mean follow up of 2.92  2.71 years, all-cause mortality was similar in both
groups (Table 1).B68 JACC Vol 64/11/Suppl B jConclusions: Prognosis is guarded with high mortality irrespective of modality of
revascularization strategy in ULMCA occlusion presenting with STEMI. However, pa-
tients undergoing PCI had a signiﬁcant decrease in overall in-hospital mortality and tended
to show a decrease in in-hospital mortality for patients presenting with cardiogenic shock.
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Background: Limited data are available on the clinical outcomes of second-genera-
tion DES (2nd DES) in patients with unprotected left main coronary artery (LMCA)
lesions. We aimed to compare the clinical impacts of 2nd DES (everolimus-eluting
stent [EES] and biolimus-eluting stent [BES]) with those of sirolimus-eluting stent
(SES) and coronary artery bypass graft (CABG) in patients with unprotected LMCA
lesions and SYNTAX score 32.
Methods: We identiﬁed 333 patients with unprotected LMCA lesions and SYNTAX
score 32 between January 2003 and December 2012. The event rates of all-cause
death, cardiac death, target vessel revascularization (TVR), and major adverse cardiac
cerebrovascular events (MACCE: all-cause death, myocardial infarction [MI], stroke,
and TVR) and the composite endpoints including death, MI, and stroke were
compared between SES, EES/BES, and CABG. The exclusion criteria were previous
PCI/CABG and acute MI within 24 hours from the onset.
Results: Of the 333 patients, 111 underwent implantation of SES, 58 EES/BES (EES,
18 and BES, 40), and 164 CABG. No signiﬁcant differences existed in baseline
characteristics. Cardiac death did not signiﬁcantly differ between the 3 groups. At 2
years, all event rates of CABG except cardiac death were signiﬁcantly lower than
those of SES and not signiﬁcantly different from those of EES/BES. Moreover, TVR
and MACCE of EES/BES were signiﬁcantly lower than those of SES
Conclusions: In patients with unprotected LMCA lesions and SYNTAX score 32,
the clinical outcomes of EES/BES were better than those of SES and not signiﬁcantly
different from those of CABG.September 13–17, 2014 j TCT Abstracts/Coronary Lesions - Left Main
